Symptomatic conduction system disease in cardiac amyloidosis.
Symptomatic conduction system disease in cardiac amyloidosis and its management has been reported infrequently. We report our experience of patients with amyloidosis having symptomatic conduction system disease requiring permanent pacemaker implantation.
Mathew
V
V
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Olson
L J
LJ
Gertz
M A
MA
Hayes
D L
DL
D000368:Aged; D000686:Amyloidosis / Q000150:complications* / Q000401:mortality / Q000628:therapy; D001145:Arrhythmias, Cardiac / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D002304:Cardiac Pacing, Artificial / Q000009:adverse effects / Q000379:methods; D009202:Cardiomyopathies / Q000150:complications* / Q000401:mortality / Q000628:therapy; D017147:Defibrillators, Implantable / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006329:Heart Conduction System / Q000503:physiopathology*; D006801:Humans; D008297:Male; D015996:Survival Rate; D016896:Treatment Outcome